{"nctId":"NCT00777556","briefTitle":"Emergency Contraception Actual Use Study","startDateStruct":{"date":"2008-10"},"conditions":["Emergency Contraception"],"count":343,"armGroups":[{"label":"DR-104","type":"EXPERIMENTAL","interventionNames":["Drug: DR-104"]}],"interventions":[{"name":"DR-104","otherNames":["Plan B® 1.5","Plan B One-Step®","levonorgestrel"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Female and 11-16 years of age, inclusive\n* Subject must be requesting emergency contraception for her own use (not for use by another person) and for current (not future) use\n* Subject can read and understand English, according to her own judgment\n* Others as dictated by FDA-approved protocol","healthyVolunteers":true,"sex":"FEMALE","minimumAge":"11 Years","maximumAge":"16 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Who Appropriately Self-selected DR-104 (Plan B® 1.5) When Dispensed Under Simulated Over-the-counter (OTC) Conditions","description":"The percentage of participants who appropriately self-selected Plan B® 1.5 at the Screening/Enrollment Visit after reading the product label. Following the standard norms for a therapy to over-the-counter (Rx-to-OTC) switch process, this outcome is an evaluation of potential consumers' ability to self-diagnose the condition and that treatment with the product is appropriate for them.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.1","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Who Correctly Used DR-104 When Dispensed Under Simulated OTC Conditions","description":"The percentage of participants who having appropriately self-selected and been dispensed Plan B® 1.5, correctly used it according to product labeling. Correct use was considered to have occurred if participants reported at the Week 1 follow-up contact that she took Plan B® 1.5 within 72 hours following unprotected sexual intercourse. Following the standard norms for a therapy to over-the-counter (Rx-to-OTC) switch process, this outcome is an evaluation of potential consumers' ability to self-treat with the product according to the product instructions.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Participants With Treatment-Emergent Adverse Events (TEAE)","description":"Treatment-emergent adverse events included adverse events reported during the protocol-specified following up contacts at weeks 1, 4 and 8 or at any other participant contact for participants who took study drug.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Participants Summarized by Repeat Use of Emergency Contraception (EC)","description":"As each participant dispensed Plan B® 1.5 was only given one tablet, repeat use of emergency contraception (EC) indicates use of an EC product other than the study product. Categories reflect the number of repeat uses.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"251","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":299},"commonTop":[]}}}